Abstract
There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
Keywords: Low molecular weight heparins (LMWH), antithrombotic agents, antitumor therapy, venous thromboembolism (VTE)
Recent Patents on Anti-Cancer Drug Discovery
Title: Low Molecular Weight Heparins as Antineoplastic Agents
Volume: 3 Issue: 3
Author(s): Sergio Siragusa
Affiliation:
Keywords: Low molecular weight heparins (LMWH), antithrombotic agents, antitumor therapy, venous thromboembolism (VTE)
Abstract: There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
Export Options
About this article
Cite this article as:
Siragusa Sergio, Low Molecular Weight Heparins as Antineoplastic Agents, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (3) . https://dx.doi.org/10.2174/157489208786242287
DOI https://dx.doi.org/10.2174/157489208786242287 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Second Line Treatments in Advanced Platinum-Resistant Non Small Cell Lung Cancer. A Critical Review of Literature
Reviews on Recent Clinical Trials Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Lipid Nanoparticles and their Application in Nanomedicine
Current Pharmaceutical Biotechnology Personalized Medicine in Oncology: A Personal View with Myths and Facts
Current Clinical Pharmacology Calcium as a Molecular Target in Angiogenesis
Current Pharmaceutical Design Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry New, Substituted Derivatives of Dicarboximides and their Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry Precision Mechanics with Multifunctional Tools: How HnRNP K and HnRNPs E1/E2 Contribute to Post-Transcriptional Control of Gene Expression in Hematopoiesis
Current Protein & Peptide Science Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Current Molecular Medicine From Ontology-Based Gene Function to Physiological Model
Current Bioinformatics Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry A Comprehensive Review on Ethnomedicinal, Pharmacological and Phytochemical Basis of Anticancer Medicinal Plants of Pakistan
Current Cancer Drug Targets Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets